Marksans Pharma shares closed at 230.69 on February 13, 2025 (NSE) and has given 7.63% returns over the last 6 months. Marksans Pharma EPS has increased to Rs. 1.22 in December 2024 from Rs. 0.56 in December 2023. EBITDA stands at Rs. 82.45 crore in January 2024 up 90.42% from Rs 43.30 crore in December2023. The company has a market capitalization of Rs. 3,000 crore. It has a debt-to-equity ratio of less than 1.5 times and a free cash flow ratio of more than 100%. The company’s share price has risen by more than 20% in the last six months and by 45.45% over the past 12 months, according to data from NSE and Dion Global Solutions Limited. The stock is trading at a P/E of around 18.5. The market value of the company has risen to about Rs. 2,300 crore.
Marksans Pharma shares closed at 230.69 on February 13, 2025….
